Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantyn贸w L贸dzki, Poland.
Stock data | 2024 | Change |
---|---|---|
Price | $4.68 | N/A |
Market Cap | $75.70M | N/A |
Shares Outstanding | 16.16M | N/A |
Employees | 248.00 | N/A |